BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Strides Arcolab Limited Inks Pact With Eli Lilly and Company (LLY) for Cancer Drugs


12/5/2012 7:25:42 AM

US-based drug firm Eli Lilly and Co and domestic firm Strides ArcolabBSE -3.27 % today said they have entered into a pact to expand marketing of generic cancer medicines in the emerging markets. As a part of the arrangement, Eli Lilly will in-licence a portfolio of branded generic injectible and oral cancer medicines from Agila Specialties, the specialties division of Strides Arcolab, the companies said in a joint statement. Agila Specialties will manufacture the cancer medicines, and Lilly will register and market them in geographies across the emerging markets, it added. In addition to the initial 10 medicines included as part of the agreement, Lilly has the right to add additional high- quality branded generic oncology products to the portfolio in the future, the statement said. The two companies, however, did not disclose the financial details of the agreement. Commenting on the development, Lilly Senior Vice- President and President of its emerging markets division Jacques Tapiero said: "Building on our recent investment in a Lilly-branded generics platform in China earlier this year, this agreement will help Lilly expand its portfolio and deliver high-quality cancer medicines to patients across emerging markets".


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES